| | IMGN due diligence links:
ragingbull.altavista.com
Tuesday, 12 Dec 2000 at 8:35 PM EST
Post # of 44205
ImmunoGen (IMGN) 12/12/00
This information comes from IMGN company reports, the company website, patents, abstracts, news reports, and knowledgeable investors. It is not meant to be complete.
Start Here:
IMGN Website
immunogen.com
IMGN Website Company Overview
immunogen.com
IMGN Website CEO Message
immunogen.com
IMGN Website Publications
immunogen.com
IMGN Patents
164.195.100.11
Some IMGN Abstracts
American Association for Cancer Research abstract search
aacr.edoc.com
Abstracts from the American Association for Cancer Research as posted on the Raging Bull Message board
ragingbull.altavista.com
ragingbull.altavista.com
ragingbull.altavista.com
ragingbull.altavista.com
ragingbull.altavista.com
ragingbull.altavista.com
--------------------------------------------------------------------------------
Upcoming Conferences:
01/31/01
IBC Life Sciences Pipeline (sponsor)
Antibody Production and Downstream Processing
Creating Successful Antibody-Based Biopharmaceutical Products
January 31-February 2, 2001 - Paradise Point Resort - San Diego, CA
09:30 AM
ibcusa.com
--------------------------------------------------------------------------------
Possible Targeted Diseases (info from patents):
tumor cells
virus infected cells
microorganism infected cells
parasite infected cells
autoimmune cells (cells that produce autoantibodies)
activated cells (those involved in graft rejection or graft vs. host disease)
any other type of diseased or abnormal cells
--------------------------------------------------------------------------------
Chemotherapeutics in development for antibody conjugate drugs (info from 10k):
DM1
DC1
taxane derivatives
DNA intercalating agents such as doxorubicin derivatives
--------------------------------------------------------------------------------
Drug pipeline in chronological deal order as of 12/12/00:
03/03/99 Partnership with Smith Kline Beecham (SBH)
C242-DM1 Colorectal, Pancreatic, other solid tumors
prnewswire.com
Currently in Phase 1/2 multi-dose clinical trial to determine MTD (maximum tolerated dose) which began 9/00 and is expected to last less than a year. biz.yahoo.com Phase 1 single-dose trial continues because no adverse effects have been seen (no toxicity, no immune response seen yet as dose level increases.) Phase 1 began 12/9/99 and was expected to last 6-9 months. The tumors in "nearly all patients" have stopped growing (http://www.immunogen.com/mess_ceo.html)
Smith Kline pays for all trial costs after phase 1.
11/10/99 Purchased option to license an antibody developed by Duke and Johns Hopkins Universities
prnewswire.com
02/24/00 collaboration with SUNY Stonybrook to develop taxane based prodrugs
prnewswire.com
05/04/00 Partnership with Genentech (DNA)
anti-HER2-DM1 Breast Cancer
awaiting clinical trials
prnewswire.com
no cost to IMGN
05/05/00 Partnership with British Biotech (BBIOY)
huN901-DM1 Small-Cell Lung Cancer
Phase 1 expected to begin fourth quarter 2000
prnewswire.com
no cost to IMGN
05/08/00 Partnership with Genentech (DNA)
license to develop a TAP with any antibody Genentech has
awaiting clinical trials
prnewswire.com
no cost to IMGN
09/06/00 Partnership with Abgenix (ABGX)
license to use develop a TAP with any antibody Abgenix has
biz.yahoo.com
no cost to IMGN
10/02/00 Partnership with MorphoSys (www.morphosys.de)
unspecified cancer targets
biz.yahoo.com (deal)
morphosys.com (technology decription)
IMGN pays milestones and royalties to MorphoSys
11/29/00 Partnership with Genzyme Transgenics Corporation (GZTC)
for drug production of HuN901
biz.yahoo.com
IMGN pays Genzyme Transgenics
--------------------------------------------------------------------------------
Articles/News (most recent first):
11/29/00 (9:40AM) SG Cowen Global Healthcare Conference
talkpoint.com
11/28/00 Adams Harkness starts coverage
biz.yahoo.com
ahh.com
11/23/00 Robertson Stevens starts coverage
biz.yahoo.com
11/16/00 Stock offering of 4.6 million shares (includes 600,000 for possible oversubscription)
biz.yahoo.com
Lead managed by SG Cowen Securities Corporation and co-managed by Robertson Stephens, Inc. and Adams, Harkness & Hill, Inc.
freeedgar.com
As of 09/30/00:
a) 38,352,683 common shares outstanding (includes 4 million shares from proposed secondary)
b) 3,006,288 shares of common stock reserved for stock options at $3.63
c) 2,576,665 shares of common stock reserved for warrants at $4.35
d) shares reserved for issuance upon the exercise of other warrants in an aggregate amount equal to the quotient obtained by dividing a total of $11.1 million by the average closing sale price of common stock on the Nasdaq National Market for the five consecutive trading days preceding the date of exercise, at an exercise price equal to such average closing sale price.
11/10/00 C242-DM1
phase 1 poster presentation (First Human Data) imgn.com
press release biz.yahoo.com
early abstract aacr.edoc.com
poster #459 nddo.nl
11/09/00 Individual Investor Article
individual*investor.com/tbd/article.asp?ID=24075 (copy, paste, remove *)
11/08/00 HuN901-DM1
preclinical press release biz.yahoo.com
abstract aacr.edoc.com
poster #118 nddo.nl
10/04/00 Stephens INC starts coverage
stephens.com
10/03/00 Investors Business Daily
New Cancer Treatment Helps Biotech Recover by Gloria Lau
“This is one of the most exciting new drugs in oncology today,” said Dr. Anthony Tolcher, principal investigator and associate director of clinical research at the Institute for Drug Development in San Antonio. “There are very few drugs that come along in our cancer world that cure solid tumor cancer. The whole potential of delivering chemotherapy directly to tumors as opposed to the entire body is exciting. It’s early, but (the data are) encouraging.”
Richard L. Schilsky Biography
uchospitals.edu
09/21/00 C242-DM1 Multidose protocol begins in Chicago and is run by Richard L. Schilsky, M.D.
biz.yahoo.com
09/20/00 Leerink Swann & Co. begins Coverage
quote.bloomberg.com
09/20/00 SG Cohen Comments
cnetinvestor.com
09/20/00 The Wall Street Journal New England Edition
Heard in New England: ImmunoGen's Stream of Partners May Keep Its Investors Dancing by Andrew Caffrey
Gary Hatton, of Granaham Investment Management, Waltham, Mass., who invests in health-care stocks for mutual fund giant Vanguard, is betting the Abgenix and Genentech working partnerships will set off a chain reaction among other companies trying to design monoclonal antibodies for cancer therapy. If those two leaders in the field have decided ImmunoGen's technology is necessary, "everybody's going to want to use it," Mr. Hatton says. "They are likely to do deal after deal." He recently bought about 750,000 shares, or 2.3% of shares outstanding.
09/18/00Stevens Conference Notes by "techinvestortoo"
ragingbull.altavista.com
09/18/00 Stevens Conference Notes from the press
sfgate.com
09/07/00 SG Cohen begins coverage
cnetinvestor.com
09/07/00 Biotech Insight mention by Dr. Ronald Garren
biospace.com
08/17/00 Cashflow positive
biz.yahoo.com
07/05/00 John MacCamant Interview (IIMGN- near the 15 minute mark)
biz.yahoo.com
06/21/00 "Biotech Recommendations"
vuwin.on24.com
06/02/00 "Magic Missiles"
doubletwist.com
03/27/00 Bio2000 Dr. Sayare, IMGN CEO Presentation
informedinvestors.com (audio)
ragingbull.altavista.com (text excerpts)
etc...
05/18/98 CEO Interview
nextwavestocks.com |
|
